Benchmark Cuts Humacyte (NASDAQ:HUMA) Price Target to $10.00

by · The Markets Daily

Humacyte (NASDAQ:HUMA – Free Report) had its target price lowered by Benchmark from $11.00 to $10.00 in a research report report published on Wednesday, MarketBeat.com reports. The firm currently has a buy rating on the stock.

Other analysts also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of Humacyte in a research note on Monday, December 1st. BTIG Research reiterated a “buy” rating and issued a $6.00 price target on shares of Humacyte in a research report on Friday, November 21st. D. Boral Capital reissued a “buy” rating and issued a $25.00 price target on shares of Humacyte in a report on Monday, January 5th. Wall Street Zen lowered shares of Humacyte from a “hold” rating to a “sell” rating in a research report on Sunday, December 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Humacyte in a report on Monday, December 29th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $8.14.

Read Our Latest Stock Analysis on Humacyte

Humacyte Trading Down 6.3%

Shares of NASDAQ:HUMA opened at $1.05 on Wednesday. The company has a 50 day moving average of $1.16 and a 200-day moving average of $1.59. The firm has a market cap of $196.63 million, a P/E ratio of -4.57 and a beta of 1.93. Humacyte has a twelve month low of $0.91 and a twelve month high of $4.85. The company has a current ratio of 1.62, a quick ratio of 0.90 and a debt-to-equity ratio of 2.97.

Humacyte (NASDAQ:HUMA – Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. The company had revenue of $0.75 million for the quarter, compared to analyst estimates of $0.92 million. As a group, analysts anticipate that Humacyte will post -1.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Humacyte

A number of large investors have recently made changes to their positions in HUMA. Vanguard Group Inc. boosted its stake in Humacyte by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 7,520,055 shares of the company’s stock worth $13,085,000 after purchasing an additional 520,431 shares during the period. CenterBook Partners LP lifted its holdings in shares of Humacyte by 141.1% in the second quarter. CenterBook Partners LP now owns 3,430,255 shares of the company’s stock valued at $7,169,000 after purchasing an additional 2,007,743 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Humacyte by 33.4% in the second quarter. Geode Capital Management LLC now owns 2,948,508 shares of the company’s stock worth $6,163,000 after buying an additional 738,142 shares during the period. Marshall Wace LLP boosted its position in shares of Humacyte by 5,308.2% in the second quarter. Marshall Wace LLP now owns 2,639,194 shares of the company’s stock worth $5,516,000 after buying an additional 2,590,394 shares during the period. Finally, Private Advisor Group LLC grew its holdings in shares of Humacyte by 2.6% during the third quarter. Private Advisor Group LLC now owns 1,029,080 shares of the company’s stock valued at $1,791,000 after buying an additional 26,400 shares in the last quarter. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Company Profile

(Get Free Report)

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.

Featured Stories